A major advancement in sickle cell treatment has arrived with the NHS approval of exagamglogene autotemcel (exa-cel), a pioneering gene-editing therapy for sickle cell disease (SCD). This innovative treatment offers a potential functional cure for patients, marking a transformative step forward for thousands who have endured the severe and chronic effects of the condition.

The burden of sickle cell disease

Sickle cell disease is a serious inherited blood disorder that disproportionately affects individuals of Black African and Black Caribbean descent. The condition alters the shape of red blood cells, causing them to form a rigid, sickle-like structure. This leads to painful crises, increased risk of organ damage, and a significantly shorter life expectancy. Traditional sickle cell treatment has largely focused on managing symptoms through blood transfusions, pain medication, and frequent hospital care.

A transformative approach to sickle cell care

Exa-cel represents a paradigm shift in how we treat this condition. As a one-time gene therapy, it uses CRISPR-Cas9 gene-editing technology to modify a patient’s stem cells, enabling the production of normal haemoglobin. In clinical trials, the results have been compelling:

  • 96.6% of participants experienced a functional cure, remaining free from painful sickle cell crises.

  • All treated patients avoided hospitalisation for at least one year post-treatment.

  • Nearly 98% of participants remained hospital-free even 3.5 years later.

  • Quality of life improvements included significant reductions in pain and greater daily functioning.

NHS leads the way in adopting advanced therapies

The approval of exa-cel reflects the NHS’s leadership in bringing breakthrough treatments to patients. Through the Innovative Medicines Fund, NHS England has secured affordable access to this therapy, ensuring eligible patients can benefit without delay. Specialist centres in London, Manchester, and Birmingham will deliver this new form of sickle cell treatment, offering hope where limited options previously existed.

Expanding the reach of gene therapy

The approval of exa-cel underscores the increasing potential of gene therapy in addressing rare and inherited conditions. As CRISPR technology matures, more diseases once deemed untreatable may be met with curative, one-time therapies. The implications for biologics and personalised medicine are profound, as research expands and regulatory frameworks adapt.

For further insights into the use of CRISPR and gene therapy in rare diseases, the Wellcome Genome Campus offers accessible educational resources.

Looking ahead

The success of exa-cel is a hopeful sign of what’s possible when science, policy, and patient need align. As the world watches the evolution of gene-editing medicine, the future of sickle cell treatment appears brighter than ever.

Let’s chat about the issues affecting you. Click here to get in touch.

Back to News + Insights